Table 1. Clinical, pathological, and treatment characteristics of the patient in III–IV grades.
| Patient characteristics | Grade III, N=48 (%) | Grade IV, N=55 (%) | High-grade people, N=103 (%) |
|---|---|---|---|
| Sex | |||
| Male | 33 (68.7) | 25 (45.5) | 58 (56.3) |
| Female | 15 (31.3) | 30 (54.5) | 45 (43.7) |
| Age | |||
| Median [range] | 48 [18–71] | 48 [18–75] | 48 [18–75] |
| Histology | |||
| Glioblastoma | – | 55 (100.0) | 55 (53.4) |
| Anaplastic astrocytoma | 32 (66.7) | – | 32 (31.1) |
| Anaplastic oligodendroglioma | 14 (29.2) | – | 14 (13.6) |
| Anaplastic oligoastrocytoma | 2 (4.1) | – | 2 (1.9) |
| IDH1/2 mutation | |||
| Mutation | 14 (29.2) | 5 (9.1) | 19 (18.4) |
| Wildtype | 15 (31.2) | 41 (74.5) | 56 (54.4) |
| Undected/indetermined | 19 (39.6) | 9 (16.4) | 28 (27.2) |
| MGMT promoter methylation | |||
| Methylated | 17 (35.4) | 11 (20.0) | 28 (27.2) |
| Not methylated | 12 (25.0) | 34 (61.8) | 46 (44.7) |
| Undected/indetermined | 19 (39.6) | 10 (18.2) | 29 (28.1) |
| 1p36⁄19q13 co-deletion | |||
| Yes | 16 (33.3) | 2 (3.6) | 18 (17.5) |
| No | 32 (66.7) | 52 (94.6) | 84 (81.5) |
| Unknown | 0 (0) | 1 (1.8) | 1 (1.0) |
| KPS at study entry | |||
| 60–100 | 45 (93.7) | 52 (94.6) | 97 (94.2) |
| <60 | 3 (6.3) | 3 (5.4) | 6 (5.8) |
| GCS at study entry | |||
| 15 | 44 (91.7) | 52 (94.6) | 96 (93.2) |
| 14–13 | 3 (6.3) | 3 (5.4) | 6 (5.8) |
| <13 | 1 (2.0) | 0 (0) | 1 (1.0) |
| Presented with seizure | 9 (18.8) | 9 (16.4) | 18 (17.5) |
| Surgery | |||
| Complete resection | 44 (91.7) | 48 (87.3) | 92 (89.3) |
| Partial resection | 4 (8.3) | 6 (10.9) | 10 (9.7) |
| Biopsy | 0 (0) | 1 (1.8) | 1 (1.0) |
| Post-op treatment | |||
| TMZ with RT | 36 (75.0) | 46 (83.6) | 82 (79.6) |
| TMZ alone | 11 (23.0) | 9 (16.4) | 20 (19.4) |
| RT alone | 1 (2.0) | 0 (0) | 1 (1.0) |
IDH, isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase; KPS, karnofsky performance status; GCS, glasgow coma scale; TMZ, temozolomide; RT, radiotherapy.